Banyan Biomarkers has licensed its intellectual property related to traumatic brain injury (TBI) biomarkers to Abbott for assessment and verification .

The terms of the in a pharma licensing agreement were not disclosed.

Detecting concussions is often difficult because the physical damage may not be obvious, a CT scan is often normal and symptoms can be similar to those of other medical conditions. Failure to make a correct diagnosis may have serious implications for the patient.

In fact, the research indicates that repetitive head injury may lead to chronic traumatic encephalopathy (CTE) which shares many features of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Agreements with Abbott 2009-2014

Report: Biomarker Partnering Terms and Agreements

Report: Traumatic Brain Injury Partnering 2009-2014

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter